All In Biotech

Drug Trial Radar · NCT07822646

A Phase 3 Study of Manganese-primed Immunochemotherapy in Patients With Advanced Ovarian Cancer

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Manganese-primed Immunochemotherapy in Subjects With Advanced Ovarian Cancer

Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Oct 12, 2026

Primary completion

Apr 12, 2029

Study completion Dec 20, 2030

Sponsor

Lead sponsor
Chinese PLA General HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Epithelial ovarian cancer is the most lethal gynecologic malignancy, and most patients eventually relapse and develop resistance to available therapies. Immune checkpoint inhibitors have shown limited overall efficacy in recurrent ovarian cancer, partly because of its immunosuppressive tumor microenvironment. Manganese (Mn2+) can activate the cGAS-STING pathway and may enhance antitumor immunity and the therapeutic effects of PD-1 blockade combined with chemotherapy. Following encouraging findings from an early-phase study, a randomized, single-blind, placebo-controlled phase II trial showed that the addition of manganese chloride to anti-PD-1 antibody, nab-paclitaxel, and cisplatin improved clinical outcomes compared with placebo, with an overall manageable safety profile. Based on these findings, this phase III trial is designed to confirm the efficacy and further evaluate the safety of Mn2+-primed immunochemotherapy in patients with advanced ovarian cancer.

Conditions

  • Ovarian Cancer

Interventions

  • Manganese ChlorideDrug

    Administered by inhalation at 0.4mg/kg twice per week in the first 3-week cycle, and then inhaled 0.4mg/kg twice in the first week of each 3-week cycle thereafter

  • Nab-paclitaxelDrug

    Administered intravenously, 180-220mg/m2 on day 2 in a 3-week cycle (day 1 without Manganese priming)

  • Platinum chemotherapyDrug

    Administered intravenously, Cisplatin (60-80mg/m2) or Carboplatin (area under the curve \[AUC\] 4-6 mg/ mL per min) on day 2 in a 3-week cycle (day 1 without Manganese priming)

  • Anti-PD-1 antibodyDrug

    Administered intravenously, 200mg on day 3 in a 3-week cycle (day 2 without Manganese priming)

  • PlaceboDrug

    Administered by inhalation twice per week in the first 3-week cycle, and then inhaled twice in the first week of each 3-week cycle thereafter

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: 12 months

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Department of Obstetrics and Gynecology, Seventh Medical Center, Chinese PLA General Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Department of Bio-therapeutic, First Medical Center, Chinese PLA General Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Department of Obstetrics and Gynecology, First Medical Center, Chinese PLA General Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Peking University International Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Department of Obstetrics and Gynecology, North China University of Science and Technology Affiliated Hospital

    Tangshan, Hebei, China · Not yet recruiting

  • Department of Gynecologic Oncology, Shanxi Province Cancer Hospital

    Taiyuan, Shanxi, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.